Print

Search Results: Treatment + Pancreatic Cancer (15 results)

Combining the Immunotherapy Dostarlimab and PARP Inhibitor Niraparib for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with an Inherited or Tumor BRCA Mutation

https://www.facingourrisk.org/research-clinical-trials/study/231/immunotherapy-and-parp-inhibitor-for-advanced-or-metastatic-breast-ovarian-or-pancreatic-cancer-with-a-brca-mutation

Treatment
Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation

This study is looking at the effectiveness of combining a PARP inhibitor called niraparib and an immunotherapy called dostarlimab for treating people with an inherited BRCA mutation (found with genetic testing) or a tumor mutation (found through tumor testing) who have breast, pancreatic, ovarian, fallopian tube or primary peritoneal cancer that is metastatic or advanced and cannot be removed by surgery (unresectable).


Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)

https://www.facingourrisk.org/research-clinical-trials/study/282/study-of-the-parp-inhibitor-azd9574-alone-and-combined-with-other-cancer-medicines-to-treat-people-with-advanced-solid-cancers-certis1-study

Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas

This research involves studying a drug called AZD9574 on its own and in combination with other anti-cancer drugs in people with advanced cancer that has come back or progressed. AZD9574 is a type of targeted therapy known as a PARP inhibitor. The study aims to understand the safety, tolerance, how the drug moves in the body, how it affects the body, and its initial effectiveness.


Testing an Immunotherapy, Pembrolizumab, in Patients With Advanced Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/234/testing-an-immunotherapy-in-patients-with-advanced-solid-tumors

Treatment
Treatment study for people with advanced cancers

This study is looking at the effectiveness of an immunotherapy, pembrolizumab, in treating people who have been diagnosed with advanced solid tumors that have progressed on standard-of-care therapy.


TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

https://www.facingourrisk.org/research-clinical-trials/study/262/tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer

Treatment
Cancer treatment study for people with advanced solid tumors

The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.


Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

https://www.facingourrisk.org/research-clinical-trials/study/230/treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib

Treatment
Treatment study for people with advanced solid tumors

This study is looking whether the drug Talazoparib (also known as Talzenna) is safe and effective for treating people with advanced solid cancers (including breast, gastric, ovarian, pancreatic, prostate or other solid tumors) in people with an inherited mutation (found through genetic testing) or an acquired mutation (found with biomarker testing) in ATM, ATR, BRCA1, BRCA2, BRIP1, BAP1, BARD1, CDK12, CHEK1, CHEK2, IDH1, IDH2, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or other genes.


A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (APOLLO)

https://www.facingourrisk.org/research-clinical-trials/study/140/olaparib-or-placebo-in-patients-with-surgically-removed-pancreatic-cancer-who-have-a-brca1-brca2-or-palb2-mutation

Treatment

The usual approach for patients with curable (i.e., non-metastatic) pancreatic cancer is a combination of surgery, FDA-approved chemotherapy, radiation (in select cases), then surveillance monitoring. This means that patients are typically monitored by their oncologist for evidence that the cancer has returned (recurrence), but they receive no additional treatment after the completion of surgery and chemotherapy.

The purpose of EA2192 / APOLLO is to compare the usual approach (observation) to treatment for one year with a drug called olaparib, in patients with BRCA1, BRCA2 or PALB2 mutation. EA2192 / APOLLO will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if olaparib delays cancer recurrence compared to the usual approach of surveillance.


NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/204/nuv-868-alone-and-in-combination-with-parp-inhibitors-in-patients-with-advanced-solid-tumors

Treatment
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer

This study will test how safe and effective the experimental drug NUV-868 is by itself and in combination with a PARP inhibitor in people with advanced solid tumors. The first part of the study will include people with any solid tumor type, and the second part will include people with triple-negative breast, ovarian, pancreatic or prostate cancers only. 


SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells

https://www.facingourrisk.org/research-clinical-trials/study/117/sharon-a-clinical-trial-for-metastatic-cancer-with-an-inherited-brca-or-palb2-mutation-using-chemotherapy-and-patients-own-stem-cells

Treatment
Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation

The purpose of this study is to see whether the combination of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous (self) bone marrow stem cell infusion, is safe and effective for treating patients with advanced pancreatic cancer or Stage IV, HER2-negative breast cancer who have a BRCA1, BRCA2 or PALB2 inherited mutation. All of these treatments are given intravenously (by vein). This study is open to people who have already received a PARP inhibitor, as well as those who have not. There are no restrictions on the number of prior treatments a patient has received before enrolling.


Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)

https://www.facingourrisk.org/research-clinical-trials/study/176/investigational-parp-inhibitor-azd5305-alone-or-combined-with-other-anti-cancer-agents-in-people-with-advanced-solid-tumors-petra

Treatment
Advanced ovarian, breast, prostate or pancreatic cancer

PETRA is studying a new PARP inhibitor AZD5305 taken either alone or combined with other treatments in people with advanced ovarian, breast, prostate or pancreatic cancer with an inherited or tumor mutation in: BRCA1/2, PALB2, RAD51C or RAD51D. The treaments participants receive will depend on their cancer type, mutation and when they join the study.


Adding Pembrolizumab to Olaparib to Treat Pancreatic Cancer in People with an Inherited BRCA Mutation

https://www.facingourrisk.org/research-clinical-trials/study/164/adding-pembrolizumab-to-olaparib-to-treat-pancreatic-cancer-in-people-with-an-inherited-brca-mutation

Treatment
Metastatic pancreatic cancer and a BRCA1 or BRCA2 mutation

This study is researching whether adding the immunotherapy drug Pembrolizumab (Keytruda) to the PARP inhibitor Olaparib (Lynparza) works better than olaparib alone in treating people with metastatic pancreatic cancer who also have an inherited BRCA1 or BRCA2 mutation.  


Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/157/treatment-with-atr-inhibitor-for-advanced-or-metastatic-solid-tumors

Treatment
Advanced solid tumors

This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes linked to DNA damage repair. The study will look at response to treatment with the drug ART0380 in combination with the chemotherapy agent, gemcitabine. 


Testing the New Targeted Therapy CYH33 in Combination With the PARP Inhibitor Olaparib in People With Advanced Solid Tumors and DNA Damage Repair Mutations

https://www.facingourrisk.org/research-clinical-trials/study/168/cyh33-in-combination-with-olaparib-in-patients-with-advanced-solid-tumors-and-dna-damage-repair-mutations

Treatment
Advanced solid tumors

This study will look at safety and effectiveness of the targeted therapy CYH33 combined with the PARP inhibitor olaparib in people with advanced cancers and a DNA damage repair (DDR) gene mutation whose cancer got worse on, or after receiving a PARP inhibitor. The study will also enroll people with recurrent, platinum resistant ovarian cancer. In addition to safety and efficacy, the study will test whether the combination of CYH33 and olaparib can block tumor growth and overcome a patient’s resistance to PARP inhibitor treatment.


Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor

https://www.facingourrisk.org/research-clinical-trials/study/151/nivolumab-and-relatlimab-in-advanced-msi-h-cancers-resistant-to-prior-pd-l1-inhibitor

Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy

The purpose of this study is to evaluate the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors resistant to prior PD-L1 therapy.

Both Nivolumab and Relatlimab are a type of immunotherapy known as immune checkpoint inhibitors. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.


Pembrolizumab and Olaparib for People With Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy

https://www.facingourrisk.org/research-clinical-trials/study/127/pembrolizumab-and-olaparib-for-metastatic-pancreatic-cancer-with-homologous-recombination-deficiency-or-exceptional-response-to-platinum-chemotherapy

Treatment

This is a study for people diagnosed with metastatic pancreatic cancer with Homologous Recombination Deficiency, or whose disease has responded well to first-line or second-line platinum therapy. The goal of this study is to look at whether combining the immunotherapy drug, pembrolizumab and the PARP inhibitor, olaparib is a more effective treatment for this cancer than taking olaparib alone.

 


A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate and Pancreatic Cancer Patients

https://www.facingourrisk.org/research-clinical-trials/study/102/a-randomized-study-of-an-ehealth-delivery-alternative-for-cancer-genetic-testing-for-hereditary-predisposition-in-metastatic-breast-ovarian-prostate-and-pancreatic-cancer-patients-e-reach

Treatment

Genetic testing can be helpful to identify potential targeted treatments for some patients with metastatic cancer. But some patients have a hard time getting easy and fast testing. This study is looking at using web options to increase access to testing AND patients in this study can get genetic counseling and testing in their home! For more information visit  the E-Reach registration page


Additional Results on Clinicaltrials.gov Treatment + Pancreatic Cancer
193 results

Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach
NCT ID: NCT05764720 (https://classic.clinicaltrials.gov/show/NCT05764720)

Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer
NCT ID: NCT02128100 (https://classic.clinicaltrials.gov/show/NCT02128100)

Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
NCT ID: NCT03492671 (https://classic.clinicaltrials.gov/show/NCT03492671)

Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
NCT ID: NCT03104439 (https://classic.clinicaltrials.gov/show/NCT03104439)

A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer
NCT ID: NCT02207465 (https://classic.clinicaltrials.gov/show/NCT02207465)

Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
NCT ID: NCT05679674 (https://classic.clinicaltrials.gov/show/NCT05679674)

Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery
NCT ID: NCT05111353 (https://classic.clinicaltrials.gov/show/NCT05111353)

Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Pancreatic Cancer
NCT ID: NCT04975516 (https://classic.clinicaltrials.gov/show/NCT04975516)

Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma
NCT ID: NCT05141513 (https://classic.clinicaltrials.gov/show/NCT05141513)

Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
NCT ID: NCT03704662 (https://classic.clinicaltrials.gov/show/NCT03704662)

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer
NCT ID: NCT04484909 (https://classic.clinicaltrials.gov/show/NCT04484909)

Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma
NCT ID: NCT03991962 (https://classic.clinicaltrials.gov/show/NCT03991962)

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
NCT ID: NCT04789486 (https://classic.clinicaltrials.gov/show/NCT04789486)

Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer
NCT ID: NCT03073785 (https://classic.clinicaltrials.gov/show/NCT03073785)

Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)
NCT ID: NCT03652428 (https://classic.clinicaltrials.gov/show/NCT03652428)

Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
NCT ID: NCT02598349 (https://classic.clinicaltrials.gov/show/NCT02598349)

Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer
NCT ID: NCT06129422 (https://classic.clinicaltrials.gov/show/NCT06129422)

Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver
NCT ID: NCT05610826 (https://classic.clinicaltrials.gov/show/NCT05610826)

Feasibility of a Health Care Provider Guided Exercise Intervention Prior to Surgical Resection of Pancreatic Cancer
NCT ID: NCT05483075 (https://classic.clinicaltrials.gov/show/NCT05483075)

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
NCT ID: NCT04539808 (https://classic.clinicaltrials.gov/show/NCT04539808)

PROACTIVE: Surgical Resection Outcomes in Locally Advanced and Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy
NCT ID: NCT06132087 (https://classic.clinicaltrials.gov/show/NCT06132087)

FOLFIRINOX + NIS793 in Pancreatic Cancer
NCT ID: NCT05417386 (https://classic.clinicaltrials.gov/show/NCT05417386)

PHL Treatment in Pancreatic Cancer
NCT ID: NCT05365893 (https://classic.clinicaltrials.gov/show/NCT05365893)

Trial of Radiotherapy in Combination With TTI-101 in Patients With Borderline Resectable Pancreatic Cancer
NCT ID: NCT06141031 (https://classic.clinicaltrials.gov/show/NCT06141031)

Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
NCT ID: NCT03322995 (https://classic.clinicaltrials.gov/show/NCT03322995)

Bethanechol Prior to Pancreatic Surgery
NCT ID: NCT03572283 (https://classic.clinicaltrials.gov/show/NCT03572283)

Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
NCT ID: NCT04331041 (https://classic.clinicaltrials.gov/show/NCT04331041)

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
NCT ID: NCT04115163 (https://classic.clinicaltrials.gov/show/NCT04115163)

High Dose Omeprazole in Patients With Pancreatic Cancer
NCT ID: NCT04930991 (https://classic.clinicaltrials.gov/show/NCT04930991)

Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer
NCT ID: NCT05841706 (https://classic.clinicaltrials.gov/show/NCT05841706)

Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients With Pancreatic Cancer With Vascular Involvement
NCT ID: NCT03716531 (https://classic.clinicaltrials.gov/show/NCT03716531)

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
NCT ID: NCT03384238 (https://classic.clinicaltrials.gov/show/NCT03384238)

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
NCT ID: NCT04594772 (https://classic.clinicaltrials.gov/show/NCT04594772)

Blue and Amber Light Exposure in Patients With Rectal and Pancreatic Cancer
NCT ID: NCT06164691 (https://classic.clinicaltrials.gov/show/NCT06164691)

Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
NCT ID: NCT02843945 (https://classic.clinicaltrials.gov/show/NCT02843945)

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
NCT ID: NCT04940286 (https://classic.clinicaltrials.gov/show/NCT04940286)

CAR T Cell Immunotherapy for Pancreatic Cancer
NCT ID: NCT03323944 (https://classic.clinicaltrials.gov/show/NCT03323944)

Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer
NCT ID: NCT05296421 (https://classic.clinicaltrials.gov/show/NCT05296421)

Breath-Hold Technique for Pancreatic Stereotactic Body Radiation Therapy (SBRT) Patients
NCT ID: NCT04843306 (https://classic.clinicaltrials.gov/show/NCT04843306)

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
NCT ID: NCT05411094 (https://classic.clinicaltrials.gov/show/NCT05411094)

Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer
NCT ID: NCT03711890 (https://classic.clinicaltrials.gov/show/NCT03711890)

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
NCT ID: NCT05604560 (https://classic.clinicaltrials.gov/show/NCT05604560)

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
NCT ID: NCT04683315 (https://classic.clinicaltrials.gov/show/NCT04683315)

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
NCT ID: NCT05462496 (https://classic.clinicaltrials.gov/show/NCT05462496)

Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
NCT ID: NCT04485286 (https://classic.clinicaltrials.gov/show/NCT04485286)

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
NCT ID: NCT02451982 (https://classic.clinicaltrials.gov/show/NCT02451982)

Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)
NCT ID: NCT06001268 (https://classic.clinicaltrials.gov/show/NCT06001268)

L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
NCT ID: NCT04203641 (https://classic.clinicaltrials.gov/show/NCT04203641)

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer
NCT ID: NCT04887805 (https://classic.clinicaltrials.gov/show/NCT04887805)

Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy
NCT ID: NCT05415917 (https://classic.clinicaltrials.gov/show/NCT05415917)

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
NCT ID: NCT05132504 (https://classic.clinicaltrials.gov/show/NCT05132504)

Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer
NCT ID: NCT03970252 (https://classic.clinicaltrials.gov/show/NCT03970252)

Pilot Study of a Multimodal Prehabilitation Pancreatic Cancer Program
NCT ID: NCT03865875 (https://classic.clinicaltrials.gov/show/NCT03865875)

Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases
NCT ID: NCT03856658 (https://classic.clinicaltrials.gov/show/NCT03856658)

Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy
NCT ID: NCT04965311 (https://classic.clinicaltrials.gov/show/NCT04965311)

FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
NCT ID: NCT04141995 (https://classic.clinicaltrials.gov/show/NCT04141995)

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
NCT ID: NCT04340141 (https://classic.clinicaltrials.gov/show/NCT04340141)

huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer
NCT ID: NCT05057715 (https://classic.clinicaltrials.gov/show/NCT05057715)

LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
NCT ID: NCT02705196 (https://classic.clinicaltrials.gov/show/NCT02705196)

High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery
NCT ID: NCT02757859 (https://classic.clinicaltrials.gov/show/NCT02757859)

Fecal Microbial Transplants for the Treatment of Pancreatic Cancer
NCT ID: NCT04975217 (https://classic.clinicaltrials.gov/show/NCT04975217)

CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
NCT ID: NCT03851237 (https://classic.clinicaltrials.gov/show/NCT03851237)

Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer
NCT ID: NCT05836870 (https://classic.clinicaltrials.gov/show/NCT05836870)

Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
NCT ID: NCT04157127 (https://classic.clinicaltrials.gov/show/NCT04157127)

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations
NCT ID: NCT04548752 (https://classic.clinicaltrials.gov/show/NCT04548752)

Redefining FOLFIORINOX in Older Pancreatic Cancer Patients
NCT ID: NCT05360732 (https://classic.clinicaltrials.gov/show/NCT05360732)

Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
NCT ID: NCT05634525 (https://classic.clinicaltrials.gov/show/NCT05634525)

Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
NCT ID: NCT05241249 (https://classic.clinicaltrials.gov/show/NCT05241249)

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer
NCT ID: NCT05799274 (https://classic.clinicaltrials.gov/show/NCT05799274)

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
NCT ID: NCT03977233 (https://classic.clinicaltrials.gov/show/NCT03977233)

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
NCT ID: NCT05624918 (https://classic.clinicaltrials.gov/show/NCT05624918)

Targeted PARP or MEK/ERK Inhibition in Patients With Pancreatic Cancer
NCT ID: NCT04005690 (https://classic.clinicaltrials.gov/show/NCT04005690)

Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
NCT ID: NCT05034627 (https://classic.clinicaltrials.gov/show/NCT05034627)

A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer
NCT ID: NCT05055323 (https://classic.clinicaltrials.gov/show/NCT05055323)

Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer
NCT ID: NCT05638698 (https://classic.clinicaltrials.gov/show/NCT05638698)

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
NCT ID: NCT05539430 (https://classic.clinicaltrials.gov/show/NCT05539430)

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
NCT ID: NCT05685602 (https://classic.clinicaltrials.gov/show/NCT05685602)

EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
NCT ID: NCT05723107 (https://classic.clinicaltrials.gov/show/NCT05723107)

Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
NCT ID: NCT05209074 (https://classic.clinicaltrials.gov/show/NCT05209074)

DCE MRI in Patients With Pancreatic Cancer
NCT ID: NCT02070705 (https://classic.clinicaltrials.gov/show/NCT02070705)

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
NCT ID: NCT02600949 (https://classic.clinicaltrials.gov/show/NCT02600949)

Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
NCT ID: NCT04809766 (https://classic.clinicaltrials.gov/show/NCT04809766)

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NCT ID: NCT05837767 (https://classic.clinicaltrials.gov/show/NCT05837767)

Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer
NCT ID: NCT04820179 (https://classic.clinicaltrials.gov/show/NCT04820179)

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas
NCT ID: NCT05053971 (https://classic.clinicaltrials.gov/show/NCT05053971)

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
NCT ID: NCT05704985 (https://classic.clinicaltrials.gov/show/NCT05704985)

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
NCT ID: NCT04147494 (https://classic.clinicaltrials.gov/show/NCT04147494)

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
NCT ID: NCT04609592 (https://classic.clinicaltrials.gov/show/NCT04609592)

CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab
NCT ID: NCT05121038 (https://classic.clinicaltrials.gov/show/NCT05121038)

Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)
NCT ID: NCT04896073 (https://classic.clinicaltrials.gov/show/NCT04896073)

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
NCT ID: NCT04673448 (https://classic.clinicaltrials.gov/show/NCT04673448)

First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer
NCT ID: NCT05141149 (https://classic.clinicaltrials.gov/show/NCT05141149)

ZN-c3 + Gemcitabine in Pancreatic Cancer
NCT ID: NCT06015659 (https://classic.clinicaltrials.gov/show/NCT06015659)

A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
NCT ID: NCT06148636 (https://classic.clinicaltrials.gov/show/NCT06148636)

Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
NCT ID: NCT05068752 (https://classic.clinicaltrials.gov/show/NCT05068752)

A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT ID: NCT04477343 (https://classic.clinicaltrials.gov/show/NCT04477343)

An Investigational Scan (68Ga-FAPI-46 PET/CT) for the Imaging of Cancer-Associated Fibroblasts in Patients With Localized Pancreatic Ductal Adenocarcinoma
NCT ID: NCT05518903 (https://classic.clinicaltrials.gov/show/NCT05518903)

MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer
NCT ID: NCT05076760 (https://classic.clinicaltrials.gov/show/NCT05076760)

Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
NCT ID: NCT03484299 (https://classic.clinicaltrials.gov/show/NCT03484299)

1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
NCT ID: NCT04098081 (https://classic.clinicaltrials.gov/show/NCT04098081)

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT ID: NCT04644068 (https://classic.clinicaltrials.gov/show/NCT04644068)

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
NCT ID: NCT05631574 (https://classic.clinicaltrials.gov/show/NCT05631574)

A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
NCT ID: NCT03899636 (https://classic.clinicaltrials.gov/show/NCT03899636)

Study of a New Technique for Imaging Pancreatic Cancer
NCT ID: NCT04883775 (https://classic.clinicaltrials.gov/show/NCT04883775)

RCT of Mobile Apps & FitBit v. Usual Care
NCT ID: NCT03623464 (https://classic.clinicaltrials.gov/show/NCT03623464)

Proglumide and Chemotherapy for Metastatic Pancreatic Cancer
NCT ID: NCT05827055 (https://classic.clinicaltrials.gov/show/NCT05827055)

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
NCT ID: NCT03454035 (https://classic.clinicaltrials.gov/show/NCT03454035)

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
NCT ID: NCT04222413 (https://classic.clinicaltrials.gov/show/NCT04222413)

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
NCT ID: NCT04858334 (https://classic.clinicaltrials.gov/show/NCT04858334)

A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer
NCT ID: NCT06199466 (https://classic.clinicaltrials.gov/show/NCT06199466)

Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis
NCT ID: NCT04858009 (https://classic.clinicaltrials.gov/show/NCT04858009)

Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
NCT ID: NCT05776524 (https://classic.clinicaltrials.gov/show/NCT05776524)

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
NCT ID: NCT03935893 (https://classic.clinicaltrials.gov/show/NCT03935893)

A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.
NCT ID: NCT05497778 (https://classic.clinicaltrials.gov/show/NCT05497778)

Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
NCT ID: NCT04158635 (https://classic.clinicaltrials.gov/show/NCT04158635)

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
NCT ID: NCT03190941 (https://classic.clinicaltrials.gov/show/NCT03190941)

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT ID: NCT02830724 (https://classic.clinicaltrials.gov/show/NCT02830724)

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
NCT ID: NCT03745326 (https://classic.clinicaltrials.gov/show/NCT03745326)

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
NCT ID: NCT05984602 (https://classic.clinicaltrials.gov/show/NCT05984602)

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
NCT ID: NCT04117087 (https://classic.clinicaltrials.gov/show/NCT04117087)

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
NCT ID: NCT05014776 (https://classic.clinicaltrials.gov/show/NCT05014776)

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
NCT ID: NCT04753879 (https://classic.clinicaltrials.gov/show/NCT04753879)

Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
NCT ID: NCT03767582 (https://classic.clinicaltrials.gov/show/NCT03767582)

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
NCT ID: NCT05922930 (https://classic.clinicaltrials.gov/show/NCT05922930)

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT ID: NCT01174121 (https://classic.clinicaltrials.gov/show/NCT01174121)

ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study
NCT ID: NCT04431258 (https://classic.clinicaltrials.gov/show/NCT04431258)

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
NCT ID: NCT04851119 (https://classic.clinicaltrials.gov/show/NCT04851119)

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
NCT ID: NCT05687123 (https://classic.clinicaltrials.gov/show/NCT05687123)

Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine
NCT ID: NCT03854110 (https://classic.clinicaltrials.gov/show/NCT03854110)

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
NCT ID: NCT05736731 (https://classic.clinicaltrials.gov/show/NCT05736731)

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
NCT ID: NCT04426669 (https://classic.clinicaltrials.gov/show/NCT04426669)

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
NCT ID: NCT05733000 (https://classic.clinicaltrials.gov/show/NCT05733000)

GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
NCT ID: NCT05391126 (https://classic.clinicaltrials.gov/show/NCT05391126)

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations
NCT ID: NCT06043713 (https://classic.clinicaltrials.gov/show/NCT06043713)

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer
NCT ID: NCT04821284 (https://classic.clinicaltrials.gov/show/NCT04821284)

Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies
NCT ID: NCT02672917 (https://classic.clinicaltrials.gov/show/NCT02672917)

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT ID: NCT04550494 (https://classic.clinicaltrials.gov/show/NCT04550494)

Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
NCT ID: NCT03825289 (https://classic.clinicaltrials.gov/show/NCT03825289)

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
NCT ID: NCT05259696 (https://classic.clinicaltrials.gov/show/NCT05259696)

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
NCT ID: NCT03727880 (https://classic.clinicaltrials.gov/show/NCT03727880)

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
NCT ID: NCT04660929 (https://classic.clinicaltrials.gov/show/NCT04660929)

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
NCT ID: NCT04543071 (https://classic.clinicaltrials.gov/show/NCT04543071)

A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
NCT ID: NCT06051695 (https://classic.clinicaltrials.gov/show/NCT06051695)

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
NCT ID: NCT05554367 (https://classic.clinicaltrials.gov/show/NCT05554367)

Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma
NCT ID: NCT05440942 (https://classic.clinicaltrials.gov/show/NCT05440942)

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
NCT ID: NCT03065062 (https://classic.clinicaltrials.gov/show/NCT03065062)

Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
NCT ID: NCT02584244 (https://classic.clinicaltrials.gov/show/NCT02584244)

Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer
NCT ID: NCT04672005 (https://classic.clinicaltrials.gov/show/NCT04672005)

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
NCT ID: NCT05864144 (https://classic.clinicaltrials.gov/show/NCT05864144)

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
NCT ID: NCT05239143 (https://classic.clinicaltrials.gov/show/NCT05239143)

SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells
NCT ID: NCT04150042 (https://classic.clinicaltrials.gov/show/NCT04150042)

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT ID: NCT05254171 (https://classic.clinicaltrials.gov/show/NCT05254171)

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
NCT ID: NCT01954992 (https://classic.clinicaltrials.gov/show/NCT01954992)

The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)
NCT ID: NCT04207944 (https://classic.clinicaltrials.gov/show/NCT04207944)

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
NCT ID: NCT03682289 (https://classic.clinicaltrials.gov/show/NCT03682289)

Pancreatic Adenocarcinoma Signature Stratification for Treatment
NCT ID: NCT04469556 (https://classic.clinicaltrials.gov/show/NCT04469556)

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
NCT ID: NCT05417594 (https://classic.clinicaltrials.gov/show/NCT05417594)

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT ID: NCT03485209 (https://classic.clinicaltrials.gov/show/NCT03485209)

A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
NCT ID: NCT03816163 (https://classic.clinicaltrials.gov/show/NCT03816163)

Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
NCT ID: NCT05669482 (https://classic.clinicaltrials.gov/show/NCT05669482)

A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
NCT ID: NCT05630183 (https://classic.clinicaltrials.gov/show/NCT05630183)

Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer
NCT ID: NCT05673811 (https://classic.clinicaltrials.gov/show/NCT05673811)

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
NCT ID: NCT06115499 (https://classic.clinicaltrials.gov/show/NCT06115499)

A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
NCT ID: NCT05293496 (https://classic.clinicaltrials.gov/show/NCT05293496)

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
NCT ID: NCT05040360 (https://classic.clinicaltrials.gov/show/NCT05040360)

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT ID: NCT02632448 (https://classic.clinicaltrials.gov/show/NCT02632448)

Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
NCT ID: NCT01365169 (https://classic.clinicaltrials.gov/show/NCT01365169)

TAS102 in Combination With NAL-IRI in Advanced GI Cancers
NCT ID: NCT03368963 (https://classic.clinicaltrials.gov/show/NCT03368963)

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NCT ID: NCT05311618 (https://classic.clinicaltrials.gov/show/NCT05311618)

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
NCT ID: NCT06065059 (https://classic.clinicaltrials.gov/show/NCT06065059)

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NCT ID: NCT05252390 (https://classic.clinicaltrials.gov/show/NCT05252390)

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
NCT ID: NCT04140526 (https://classic.clinicaltrials.gov/show/NCT04140526)

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT04666688 (https://classic.clinicaltrials.gov/show/NCT04666688)

A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
NCT ID: NCT05708950 (https://classic.clinicaltrials.gov/show/NCT05708950)

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
NCT ID: NCT04396821 (https://classic.clinicaltrials.gov/show/NCT04396821)

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
NCT ID: NCT04429542 (https://classic.clinicaltrials.gov/show/NCT04429542)

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
NCT ID: NCT05945823 (https://classic.clinicaltrials.gov/show/NCT05945823)

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT05070247 (https://classic.clinicaltrials.gov/show/NCT05070247)

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NCT ID: NCT05215574 (https://classic.clinicaltrials.gov/show/NCT05215574)

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT ID: NCT05887492 (https://classic.clinicaltrials.gov/show/NCT05887492)

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
NCT ID: NCT04925284 (https://classic.clinicaltrials.gov/show/NCT04925284)

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NCT ID: NCT04332653 (https://classic.clinicaltrials.gov/show/NCT04332653)

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
NCT ID: NCT04924075 (https://classic.clinicaltrials.gov/show/NCT04924075)

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
NCT ID: NCT04956640 (https://classic.clinicaltrials.gov/show/NCT04956640)

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
NCT ID: NCT05477576 (https://classic.clinicaltrials.gov/show/NCT05477576)

A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
NCT ID: NCT05716295 (https://classic.clinicaltrials.gov/show/NCT05716295)

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
NCT ID: NCT05997056 (https://classic.clinicaltrials.gov/show/NCT05997056)

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT ID: NCT05379985 (https://classic.clinicaltrials.gov/show/NCT05379985)

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
NCT ID: NCT04319757 (https://classic.clinicaltrials.gov/show/NCT04319757)

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
NCT ID: NCT05907304 (https://classic.clinicaltrials.gov/show/NCT05907304)

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
NCT ID: NCT05247905 (https://classic.clinicaltrials.gov/show/NCT05247905)

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
NCT ID: NCT05039177 (https://classic.clinicaltrials.gov/show/NCT05039177)

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT ID: NCT03785249 (https://classic.clinicaltrials.gov/show/NCT03785249)


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.